Your browser doesn't support javascript.
loading
Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
Chen, Liqun; Mooso, Benjamin A; Jathal, Maitreyee K; Madhav, Anisha; Johnson, Sherra D; van Spyk, Elyse; Mikhailova, Margarita; Zierenberg-Ripoll, Alexandra; Xue, Lingru; Vinall, Ruth L; deVere White, Ralph W; Ghosh, Paramita M.
Affiliation
  • Chen L; VA Northern California Health Care System, Mather, California, USA.
Clin Cancer Res ; 17(19): 6218-28, 2011 Oct 01.
Article in En | MEDLINE | ID: mdl-21844010
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptor, ErbB-2 / Receptor, ErbB-3 / ErbB Receptors / Androgen Antagonists / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: United States Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Receptor, ErbB-2 / Receptor, ErbB-3 / ErbB Receptors / Androgen Antagonists / Antineoplastic Agents Type of study: Prognostic_studies Limits: Animals / Humans / Male Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2011 Document type: Article Affiliation country: United States Country of publication: United States